Exscientia

Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Exscientia's mission is to become the leading provider of AI-driven drug discovery and design through the use of Artificial Intelligence and Automation. We strive to make the process of drug discovery and development faster, more accurate and more cost-effective.

Exscientia's vision is to revolutionize how drugs are discovered and developed, resulting in life-saving treatments that are available to more people around the world. We want to create an industry-leading platform that accelerates drug development and brings revolutionary new drugs to market faster.

Exscientia has been the recipient of several awards, including the 2020 Clerks Award for innovation in drug discovery and the 2018 Red Herring Top 100 Europe Award for emerging companies in drug discovery.